Literature DB >> 16205900

[Prognostic factors in prostate cancer].

H Bonkhoff1.   

Abstract

Since several therapeutic options are currently available for clinically organ-confined prostate cancer, morphological parameters have rapidly emerged as prognostic factors to stratify patients into different therapeutic modalities. In addition to the PSA value, pathologic stage, as defined by the TNM system, Gleason grade and the surgical margin status, other markers have prognostic implications. This includes the percent pattern 4/5 cancer, tumor volume, intraductal spread, large volume perineural invasion and molecular markers. This review discusses the methods of sampling and reporting in prostate pathology with an emphasis on well established and new prognostic factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205900     DOI: 10.1007/s00292-005-0792-z

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  12 in total

Review 1.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

Authors:  D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

2.  The role of intraductal carcinoma in the natural history of prostatic adenocarcinoma.

Authors:  J E McNeal
Journal:  Eur Urol       Date:  2001-04       Impact factor: 20.096

Review 3.  Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.

Authors:  D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

Review 4.  Molecular markers of prostate cancer outcome.

Authors:  David I Quinn; Susan M Henshall; Robert L Sutherland
Journal:  Eur J Cancer       Date:  2005-04       Impact factor: 9.162

5.  Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression.

Authors:  H J Dawkins; L N Sellner; G R Turbett; C A Thompson; S L Redmond; J E McNeal; R J Cohen
Journal:  Prostate       Date:  2000-09-01       Impact factor: 4.104

Review 6.  Pathological and molecular aspects of prostate cancer.

Authors:  Angelo M DeMarzo; William G Nelson; William B Isaacs; Jonathan I Epstein
Journal:  Lancet       Date:  2003-03-15       Impact factor: 79.321

Review 7.  Gleason grading and prognostic factors in carcinoma of the prostate.

Authors:  Peter A Humphrey
Journal:  Mod Pathol       Date:  2004-03       Impact factor: 7.842

Review 8.  Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy.

Authors:  Jonathan I Epstein
Journal:  Mod Pathol       Date:  2004-03       Impact factor: 7.842

Review 9.  Radical prostatectomy for carcinoma of the prostate.

Authors:  Makoto Ohori; Michael Kattan; Peter T Scardino; Thomas M Wheeler
Journal:  Mod Pathol       Date:  2004-03       Impact factor: 7.842

Review 10.  Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.

Authors:  F Schröder; B Tribukait; A Böcking; R DeVere White; L Koss; M Lieber; B Stenkvist; A Zetterberg
Journal:  Scand J Urol Nephrol Suppl       Date:  1994
View more
  1 in total

1.  [Active surveillance of localized prostate cancer. Significance of prostate core needle biopsies].

Authors:  J Rüschoff; P Middel; P Albers
Journal:  Pathologe       Date:  2008-09       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.